FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer.
作者： Wenjun Chen , Jianguo Shen , Tao Pan , Wenxian Hu , Zinong Jiang
关键词: Epirubicin 、 Oxaliplatin 、 Capecitabine 、 Oncology 、 Regimen 、 FOLFOX 、 Chemotherapy 、 Medicine 、 Chemotherapy regimen 、 Internal medicine 、 Cancer
摘要: Neoadjuvant chemotherapy is the preferred treatment of advanced gastric cancer. However, choice an optimal regimen remains controversial. The present study aimed to assess effectiveness preoperative with EOX and FOLFOX in Chinese patients A total 87 26 underwent regimens, respectively, for cancer between July 2004 September 2012. Clinicopathological characteristics, pathological T stage, N stage response tumour regression were retrospectively compared two groups. Following neoadjuvant chemotherapy, a higher number manifested deeper invasive group than those (P=0.047). In addition, also exhibited metastatic lymph nodes (67.8%) (57.7%) (P=0.000). groups, 4 (4.6%) 3 (11.5%) cases complete observed, respectively. (38.5%) grades (19.5%) Results suggest that may be more effective as suitable younger subjected individual chemotherapy.
sci-hub.se 参考文章(25)
William B. Robb, Christophe Mariette, Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from Neoadjuvant Chemotherapy? Recent results in cancer research. ,vol. 196, pp. 241- 268 ,(2012) , 10.1007/978-3-642-31629-6_17
V. Boige, J. Pignon, B. Saint-Aubert, P. Lasser, T. Conroy, O. Bouché, P. Segol, L. Bedenne, P. Rougier, M. Ychou, Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial Journal of Clinical Oncology. ,vol. 25, pp. 4510- 4510 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4510
Yi Liao, Zu‐li Yang, Jun‐sheng Peng, Jun Xiang, Jian‐ping Wang, None, Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. Journal of Gastroenterology and Hepatology. ,vol. 28, pp. 777- 782 ,(2013) , 10.1111/JGH.12152
A TROTTI, A COLEVAS, A SETSER, V RUSCH, D JAQUES, V BUDACH, C LANGER, B MURPHY, R CUMBERLIN, C COLEMAN, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology. ,vol. 13, pp. 176- 181 ,(2003) , 10.1016/S1053-4296(03)00031-6
Katja Ott, Florian Lordick, Ken Herrmann, Bernd-Joachim Krause, Christoph Schuhmacher, Jörg Rüdiger Siewert, The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. ,vol. 11, pp. 1- 9 ,(2008) , 10.1007/S10120-007-0448-1
Anne-Marie Mandard, Frédéric Dalibard, Jean-Claude Mandard, Jacques Marnay, Michel Henry-Amar, Jean-François Petiot, Alain Roussel, Jacques-Henry Jacob, Philippe Segol, Guy Samama, Jean-Marie Ollivier, Sylvie Bonvalot, Marc Gignoux, Pathologic Assessment of Tumor Regression After Preoperative Chemoradiotherapy of Esophageal Carcinoma. Clinicopathologic Correlations Cancer. ,vol. 73, pp. 2680- 2686 ,(1994) , 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
Lei Ge, Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: A meta-analysis World Journal of Gastroenterology. ,vol. 18, pp. 7384- 7393 ,(2012) , 10.3748/WJG.V18.I48.7384
Andrew M. Lowy, Paul F. Mansfield, Steven D. Leach, Richard Pazdur, Pamela Dumas, Jaffer A. Ajani, Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Annals of Surgery. ,vol. 229, pp. 303- 308 ,(1999) , 10.1097/00000658-199903000-00001
D. Beddy, J. M. P. Hyland, D. C. Winter, C. Lim, A. White, M. Moriarty, J. Armstrong, D. Fennelly, D. Gibbons, K. Sheahan, A Simplified Tumor Regression Grade Correlates with Survival in Locally Advanced Rectal Carcinoma Treated with Neoadjuvant Chemoradiotherapy Annals of Surgical Oncology. ,vol. 15, pp. 3471- 3477 ,(2008) , 10.1245/S10434-008-0149-Y
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026